Aklavine

DB19070ExperimentalSmall molecule

Aklavine is under investigation in clinical trial NCT03026842 (Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With T(8;21)).

Formula / weight: C₃₀H₃₅NO₁₀ · 569.607 g/mol (avg)
Also known as: 1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(dimethylamino)-.alpha.-l-lyxo-hexopyranosyl)oxy)-, methyl ester, (1r,2r,4s)- · Aclacinomycin t
Code names: MA-144T1

Resolves to

Compound

UNIIT87WN25BNWCAS66676-88-8ChEMBLCHEMBL3040622ChEBI77979KEGGC18634

Structure

InChIKeyLJZPVWKMAYDYAS-QKKPTTNWSA-NSMILES[H][C@@]1(C[C@@H]([C@H](O)[C@H](C)O1)N(C)C)O[C@H]1C[C@](O)(CC)[C@H](C(=O)OC)C2=CC3=C(C(O)=C12)C(=O)C1=C(O)C=CC=C1C3=O

What you can answer from here — as of September 19, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Aklavine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account